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This study examines a new method for the remote loading of doxorubicin into liposomes. It was shown that doxorubicin can be loaded to a
level of up to 98% into large unilamellar vesicles composed of egg phosphatidylcholine/cholesterol (7/3 mol/mol) with a transmembrane
phosphate gradient. The different encapsulation efficiencies which were achieved with ammonium salts (citrate 100%, phosphate 98%, sulfate
95%, acetate 77%) were significantly higher as compared to the loading via sodium salts (citrate 54%, phosphate 52%, sulfate 44%, acetate 16%).
Various factors, including pH-value, buffer capacity, solubility of doxorubicin in different salt solutions and base counter-flow, which likely has an
influence on drug accumulation in the intraliposomal interior are taken into account. In contrast to other methods, the newly developed remote
loading method exhibits a pH-dependant drug release property which may be effective in tumor tissues. At physiological pH-value doxorubicin is
retained in the liposomes, whereas drug release is achieved by lowering the pH to 5.5 (approximately 25% release at 25 °C or 30% at 37 °C within
two h). The DXR release of liposomes which were loaded via a sulfate gradient showed a maximum of 3% at pH 5.5.
© 2006 Elsevier B.V. All rights reserved.Keywords: Doxorubicin; EPC/cholesterol liposome; Diammonium hydrogen phosphate; Cryo-electron microscopy; Remote loading; pH-triggered release1. Introduction
Doxorubicin (DXR) is a widely used anticancer drug [1]. It
has a broad spectrum of reactivity and shows excellent anti-
neoplastic activity against a multitude of human cancer diseases
[2–5]. However, the clinical use of DXR is hampered by acute
and subacute side effects such as vomiting, bone marrow
suppression, alopecia, mucositis and drug-induced dose-limit-
ing irreversible cardiotoxicity and myelosuppression [6–8]. The
mechanism of action of DXR has been extensively investigated.
DXR is a DNA-intercalating agent and a topo-isomerase II
inhibitor [9]. It is also known to form free radicals [10], which
produce lipid peroxidation and can damage DNA with double
and single strand breaks and abasic (apurin or apyrimidin)
lesions, all of which may be implicated by its mechanism of
action [5,7,11–14]. However it has not been shown that⁎ Corresponding author. Tel.: +49 761 203 6327, fax: +49 761 203 6326.
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doi:10.1016/j.bbamem.2006.05.028anthracyclines form radicals in the nucleus and therefore this
mechanism is still under discussion [15]. It has been previously
shown that liposomal-associated DXR delivery systems
improve the therapeutic index [4,16–19]. In general, liposomal
DXR exhibits efficiencies comparable to those of conventional
anthracycline cytostatics, but with less general side effects
especially with regard to cardiotoxicity [4,8]. It has been shown
that the in vivo toxicity of DXR decreases with the increase of
the drug-to-lipid ratio [20]. Therefore, achieving high encapsu-
lation efficiencies of DXR into liposomes is desirable. Until
now four different strategies of loading DXR into liposomes
have been described. These different loading techniques are
driven by the use of a pH-, manganese-, sulfate- or citrate-
gradient. All of these concepts follow one principle, i.e., that the
free DXR base diffuses inside the liposome where a modifica-
tion of the drug occurs which inhibits membrane repermeation
and results in accumulation inside the liposomes.
In the case of the transmembrane pH-gradient the interior of
the liposome is acidic, whereas the exterior pH-value is adjusted
to physiological conditions. The uncharged DXR which is
incubated with these liposomes diffuses into the vesicles and
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DXR can no longer pass the bilayer and is trapped inside the
liposomes [21–24].
The DXR loading into liposomes via a transmembrane
manganese-gradient is based on the formation of intravesicular
DXR–Mn2+-complexes [25,26]. It has been well described that
DXR forms chelate complexes with multivalent cations [27,28].
It has also been noted, that DXR can be efficiently loaded
into liposomes with a transmembrane sulfate- or citrate-gradient
[24,29–35]. In both concepts DXR precipitates in bundles of
fibers in the liposomal interior [23,36].
Two liposomal formulations of DXR approved for human
use are currently on the market, Myocet® and Caelyx® (EU)
respectively Doxil® (US).
Myocet® consists of EPC and is loaded via a citric acid
gradient. Doxil® is composed of MPEG-DSPE, HSPC and
Cholesterol and is loaded by an ammonium sulfate gradient.
In the present study further gradients were evaluated for
efficient loading of DXR and it could be shown that DXR
precipitates not only in the presence of citrate and sulfate ions,
but also in the presence of phosphate and acetate ions. DXR
could be efficiently loaded into liposomes with a transmem-
brane (NH4)2HPO4-gradient. This turns out to be a superior
alternative technique of loading DXR into lipid vesicles. These
liposomes show drug release rates dependent on the extra-
liposomal pH. This may improve the applicability of DXR
liposomes at tumor sites, which exhibit a decreased pH-value
compared with the non-tumor environment. Furthermore, this
study contributes to the understanding of the different loading
mechanisms of DXR into liposomes.
2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (EPC) was a generous gift from Lipoid
(Ludwigshafen, Germany). Cholesterol (Chol) was purchased from Caelo
(Caesar und Lorentz, Hilden, Germany). Doxorubicin HCl was obtained from
the European Directorate for the Quality of Medicines (Strasbourg, France) and
Caelyx® from essex pharma (Munich, Germany). Sepharose CL-4B was
purchased from Amersham Biosciences (Uppsala, Sweden). All chemicals were
of analytical grade.
2.2. Preparation of liposomes
A lipid mixture of egg phosphatidylcholine (EPC) and cholesterol (Chol)
(mol/mol 7/3) was dissolved in ethanol and subsequently the solvent was
removed under reduced pressure at 35 °C, followed by evaporation under high
vacuum. The resulting lipid film was hydrated with the appropriate solutions by
gentle mixing. The generated multilamellar vesicles (MLV) were extruded 21
times through a 80 nm pore sized polycarbonate membrane (Whatman,
Maidstone, Kent, UK) using a LiposoFast-Basic™ Extruder (Avestin, Ottawa,
Canada).
2.3. Preparation of ion gradient for drug encapsulation
Liposomes were passed through a Sepharose CL-4B column equilibrated
with an isotonic HEPES buffered saline (HBS), 140 mM NaCl, 10 mM
HEPES ([4-(2-hydroxyethyl)-piperazino]-ethanesulfonic acid, pH 7.4) to
replace the extra-liposomal solution. The eluted liposomes were diluted
with isotonic HEPES buffer to yield a final lipid concentration of 5 mM.Subsequently, doxorubicin HCl was added to the liposomal dispersion to
achieve a drug to lipid ratio of 1/3 (mol/mol). The loading process was
carried out at 7 °C for 12 h.
2.4. Size determination
Liposomal samples were diluted with freshly filtrated isotonic HEPES buffer
(0.22 μm Minisart, Sartorius AG, Göttingen, Germany) in order to yield an
appropriate counting rate. All samples were placed into the specimen holder of a
Zetamaster S (Malvern Instruments Ltd., Malvern, UK) 5 min prior to the start of
measurement in order to allow equilibration to room temperature. Data were
calculated by contin mode.
2.5. Determination of encapsulation efficiency (EE)
The separation of liposomes from free DXR was performed by size
exclusion chromatography (SEC) or alternatively by ultracentrifugation.
Separation by SEC was achieved using a Sepharose CL-4B column
(0.7 cm×10 cm). Separation of 100 μl liposomes from non encapsulated DXR
was carried out by elution with isotonic HEPES buffer (pH 7.4). Ultracen-
trifugation was performed at 130000×g for 3 h at 20 °C (Optima LE-80,
Beckman Instruments Inc., Palo Alto, USA), and the supernatant was removed.
The liposome pellet was redispersed in HBS pH 7.4.
The DXR concentration was determined at 495 nm (Uvikon 933 A, Kontron
Instruments, Italy) after lysis of the liposomes with Triton X-100 (final
concentration 0.5% v/v).
2.6. Solubility of DXR
The solubility of DXR was investigated in various solutions of ammonium
salts of sulfate (300 mM), hydrogen phosphate (300 mM), acetate (600 mM) and
citrate (300 mM). The pH-values were adjusted with ammonia or hydrochloric
acid. The salt solutions were added to lyophilized DXR. Each sample was
vortexed for 1 min and incubated at 20 °C for 12 h. The precipitate was
separated from the supernatant by centrifugation (10000×g; 10 min). DXR in the
supernatants was quantified photometrically at 495 nm.
2.7. Cryo-transmission electron microscopy
Liposome formulations were diluted with the extra-vesicular buffer to reach
a total lipid concentration of 4–7 mM. Copper grids (Science Service, Munich,
Germany) were prepared according to a standard method [37]. After placing a
drop of the sample on the grid most of the liquid was removed with filter paper,
leaving a thin film stretched over the holes. The samples were shock-frozen by
dipping into liquid ethane and cooled to 90 K by liquid nitrogen. The samples
were transferred to the microscope (Zeiss CEM 902, Carl Zeiss, Oberkochen,
Germany) as described elsewhere [38] and then examined at approximately
100 K. Zero-loss filtered images were taken by a slow scan charge-coupled
device (SSCCD) camera under low-dose conditions, i.e. using the minimal dose
focusing device.
2.8. Determination of the inner pH-value of liposomes
The internal pH of the liposomes was measured using the fluorescent
probe HPTS (8-hydroxypyrene-1,3,6-trisulfonic acid, pyranine) [39–42].
Liposomes were prepared as described above with the exception that HPTS
(0.5 mM) was added to the salt solution for hydration. Free HPTS was
separated by gel filtration using a Sephadex G-50 column. The internal pH-
value was determined by the excitation spectra of HPTS immediately after the
separation of free HPTS from the liposomal HPTS fraction. HPTS has two
excitation maxima. One occurs at 411 nm under isosbestic, pH independent
conditions and the second is pH dependent and occurs at 455 nm. The
calibration curve is based on the equation pH=pK+log (F455/F411), where
the latter term is the logarithm of the ratio of the fluorescence intensities at
512 nm using excitation wavelengths of 455 nm or 411 nm. These
measurements were performed with a Perkin-Elmer fluorescence spectrometer
LS 50B (Perkin-Elmer, Rodgau Jügesheim, Germany).
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The liposomal release of DXR was quantified by the fluorescence
dequenching of self-associated DXR in liposomes upon dilution outside the
liposomes [43,44]. Measurements were performed at λexc 480 nm and λem
590 nm [33]. Liposomal drug release was investigated in HEPES buffer (10 mM
HEPES, 140 mM sodium chloride and 5 mM succinic acid) at 25 °C and 37 °C.
The pH-value of the HEPES buffer was adjusted to pH-values of 5.5, 6.5 or 7.4
with sodium hydroxide. The increase of fluorescence intensity was followed in
the timedrive mode. 100% dequenched DXR (total DXR) was determined after
addition of Triton X-100 (0.5% v/v) [33].3. Results
In this study solubility of doxorubicin (DXR) in different salt
solutions as well as liposomal encapsulation of DXR by the use
of a transmembrane gradient of these solutions was examined.
In order to avoid degradation of the temperature- and light-
sensitive drug, the loading of DXR into the liposomes was
performed at 7 °C protected from light.
3.1. Solubility
As shown in Fig. 1, doxorubicin exhibits very low
solubility at 20 °C in 300 mM phosphate, sulfate, citrate and
acetate solutions over the range of pH 5–8.5. Sodium and
ammonium salt solutions show approximately the same DXR
solubility (data not shown). The results for DXR solubility in
citrate solution are in agreement with reports on the
solubility of lipophilic cationic drugs in citrate solutions
[31,45].
The solubility of DXR in phosphate, citrate and acetate
buffer is dependent on pH-value. The solubility of DXR
decreases with increasing pH-value. The DXR solubility in
phosphate solutions was not determined at pH 4 because the
viscosity at higher DXR concentrations strongly increased by
forming a clear, red semi-solid dispersion.
In ammonium sulfate solution the solubility of DXR was
almost constant at about 0.2 mg/ml up to a pH-value of 7.5,Fig. 1. Solubility of DXR in different salt solutions as a function of pH. The
solutions were added to lyophilized DXR and vortexed for 1 min. After
incubation of the samples at 20 °C for 12 h, the solubilized DXR in the
supernatant was quantified (n=3).which is close to the pKa-value of 8.1 for the amino group [30].
At higher pH the solubility decreased to lower values which
were comparable with those of other salt solutions.
3.2. Encapsulation of DXR by the use of several salt gradients
DXR liposomes loaded with gradients of NH4
+-salts showed a
higher EE than those loaded by sodium salts (Fig. 2). The
liposomal preparations generally showed a constant particle size
and polyindex during the loading process (Table 1). The EE
declined in the line: citrate>phosphate>sulfate>acetate. Among
the ammonium salts, only acetate showed a DXR loading below
90%. All salt gradients resulted in active DXR loading, when
compared to the minimal theoretical EE, which is calculated by
the ratio of inner liposomal to total aqueous volume [46].
3.3. Influence of the intravesicular phosphate concentration on
the encapsulation efficiency (EE)
Dried lipid was hydrated with various buffers containing
either HBS or 50, 100, 200 or 300 mM ammonium phosphate
(pH was adjusted to 7.2 with 0.1 N NaOH). The size of the
liposomes after extrusionwas around 100 nm (±11nm) (Table 2).
External phosphate was removed by size exclusion chromato-
graphy with HBS.
After the addition of lyophilized DXR and 12 h of incubation
at 7 °C, the EE increased up to 98% with a drug to lipid ratio of
1:3 (mol/mol) at a phosphate concentration of 300 mM inside
the liposomes. The lowest DXR EE (2.8%) was achieved with
10 mM HEPES buffer, containing no phosphate ions.
3.4. Ammonium salt gradient
Liposomes were prepared by hydrating the lipid film with
300 mM (NH4)2HPO4 buffer (pH 7.4) and extrusion through
80 nm membranes. The extraliposomal buffer was exchanged
through different buffers (Table 3) by size exclusion chromato-
graphy. The transmembrane ammonium gradient induces a
transmembrane pH-gradient, which is due to an increase of
proton concentration inside the liposomes. This was measured
using encapsulated HPTS as pH-sensitive probe. Table 2 shows
that the intraliposomal pH-value is unmodified when the interior
contains the same ammonium concentration as outside the
liposome, or when no ammonium ions were present inside the
liposomes. This study shows that in case of an ammonium
gradient the capacity of the phosphate buffer inside the vesicles is
not sufficient and therefore the intravesicular pH drops to <5.5.
3.5. Loading of DXR via sodium phosphate gradient with
different interior pH-values
Liposomes were prepared with intraliposomal sodium
phosphate buffer (300 mM Na2HPO4) of various pH-values
(pH 3, 4, 5, 6 and 7.2). As shown in Fig. 3, lower pH-values
resulted in a higher EE of DXR.
However, the high EE of (NH4)2HPO4 could not be achieved
with a Na2HPO4 gradient when combined with a pH-gradient.
Fig. 2. Efficiency of encapsulation of DXR in EPC/Chol (7/3 mol/mol, 5 mM
lipid concentration) liposomes driven by various salt gradients. The lipid
formulations were prepared with a molar drug/lipid ratio of 1:3. The lipid film
was hydrated with 300 mM salt solution adjusted to pH 7.4. Liposomes were
incubated with DXR for 12 h at 7 °C (n=3).
Table 2
Encapsulation efficiency (EE) of DXR in EPC/Chol (7/3 mol/mol) liposomes by
varying the intraliposomal ammonium phosphate concentration (n=3)
(NH4)2HPO4
concentration [mM]
EE [%] (±sd) Size [nm] (±sd)
0 2.81 (0.83) 84 (0.4)
50 23.52 (4.02) 102 (1.4)
100 61.03 (6.77) 114 (3.6)
200 83.35 (7.97) 95 (1.5)
300 97.98 (1.52) 92 (1.6)
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Cryo-TEMwas used for visualization of DXR liposomes and
a representative micrograph is shown in Fig. 4. The micrograph
4 reveals liposomes prepared in 300 mM (NH4)2HPO4 solution
after the extra-vesicular buffer was exchanged with HBS.
Liposomes were loaded with DXR with a ratio of DXR to lipid
of 1/3 (mol/mol).
As shown in Fig. 4, entrapped and precipitated DXR forms
bundles that appear as linear structures and induce a change in
liposomal shape, resulting in a characteristic “coffee bean”-
structure. When the DXR/lipid ratio is increased to higher
values than 1/3 (mol/mol), the free drug bundles can be found
coexisting with empty liposomes. This was reflected by
continuously decreasing EE (data not shown).
3.7. Leakage of DXR liposomes loaded via a phosphate
gradient
Stability of DXR liposomes and drug release was examined
under conditions approaching those which would be encoun-
tered following their application. These include contact withTable 1
Change in particle size of the liposomes during remote loading with DXR (the
intraliposomal salt concentration was 300 mM (n=3))
Salt-gradient Particle size
[nm] before
loading (±sd)
Polyindex
before
loading (±sd)
Particle size
[nm] after
loading (±sd)
Polyindex
after loading
(±sd)
(NH4)2HPO4 132.4 (±0.6) 0.094 (±0.036) 129.3 (±3.7) 0.132 (±0.044)
Na2HPO4 113.4 (±1.2) 0.109 (±0.044) 113.4 (±1.6) 0.034 (±0.008)
(NH4)2SO4 128.4 (±0.9) 0.046 (±0.034) 129.2 (±2.9) 0.128 (±0.015)
Na2SO4 115.3 (±2.9) 0.057 (±0.039) 111.8 (±1.9) 0.101 (±0.03)
NH4-Acetate 116.7 (±3.2) 0.105 (±0.031) 115.9 (±1.0) 0.095 (±0.03)
Na-Acetate 113.4 (±1.2) 0.109 (±0.044) 113.4 (±1.6) 0.034 (±0.008)
NH4-Citrate 115.7 (±1.0) 0.136 (±0.133) 114.9 (±1.2) 0.061 (±0.037)
Na-Citrate 150.3 (±4.6) 0.074 (±0.05) 151.7 (±3.8) 0.351 (±0.059)physiological fluids at pH 7.4, pH 6.5 of tumor tissues [47] and
pH 5.5 after uptake in endosomal compartments.
The drug release properties of liposomes, which were loaded
via a transmembrane phosphate gradient, differ completely from
vesicles, which are loaded with a sulfate gradient.
The DXR release of liposomes which were loaded via a
sulfate gradient showed a maximum of 2% at pH 5.5 and the
influence of pH on the release property was negligible (Fig. 5B).
In contrast, liposomes loaded by a phosphate gradient show a
DXR release dependant on the pH-value of the extraliposomal
buffer. Leakage of DXR at pH 7.4 is less than 2% but leakage
increases with decreasing pH (Fig. 5A). At pH 6.5 and 5.5 the
drug release is influenced by the extraliposomal ratio of
positively charged DXR to uncharged DXR.
Furthermore release experiments have been performed with
these liposomes at 37 °C. pH dependent release from EPC/Chol
liposomes was found to be slightly increased which might be
due to increased DXR solubility and/or membrane fluidity
(Figs. 5A and 6A).
Release experiments of DXR at 37 °C were also performed
with Caelyx® and showed only maximum release of 2.5% DXR
(Fig. 6B), which corresponds to our findings achieved at 25 °C
with EPC/Chol liposomes which were also loaded by
ammonium sulfate gradient (Fig. 5B).
4. Discussion
Loading liposomes with DXR via phosphate-gradient is a
new, potent and alternative remote-loading method, which takes
into account the thermo- and light-sensitive properties [44,48]
of the drug.Table 3
Correlation between ammonium- and pH-gradient of EPC/Chol (7/3 mol/mol)
liposomes with different intra- and extravesicular buffers (n=3)
Hydration buffer Elution buffer NH4
+-
gradient
Intraliposomal
pH-value
300 mM (NH4)2HPO4
+0.5 mM HPTS pH 7.4
HBS pH 7.4 (+) <5.5
300 mM
(NH4)2HPO4 pH 7.4
(−) 7.4
300 mM (NH4)2SO4
pH 7.4
(−) 7.4
300 mM Na2HPO4
+0.5 mM HPTS pH 7.4
HBS pH 7.4 (−) 7.4
300 mM Na2HPO4
pH 7.4
(−) 7.4
Fig. 3. Loading of DXR into EPC/Chol (7/3 mol/mol) liposomes prepared with
sodium phosphate buffers of different pH-values (n=3).
Fig. 5. Release of doxorubicin from EPC/Chol (7/3 mol/mol) liposomes at
25 °C. Doxorubicin was encapsulated by ammonium phosphate-gradient (A) or
ammonium sulfate-gradient (y-axis extended) (B) and drug release was analyzed
in 10 mM HEPES, 140 mMNaCl buffer pH 7.4 (x), pH 6.5 (▴) or pH 5.5 (●) at
25 °C. (n=3 in panel A, n=4 in panel B).
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synergistic effects, both of which result in the fact that DXR can
no longer pass the lipid membrane. On the one hand loading is
driven by protonation and charging of DXR within the
liposome, on the other by precipitation of DXR in the
hydrophilic interior of the vesicle when the concentration of
DXR solubility is exceeded.
By means of a stable pH-gradient, DXR is protonated in the
acidic interior of the liposome. When the extraliposomal pH is
selected in that way, only a small part of the DXR is protonated.
The free uncharged base is then able to pass the membrane so
that there is intra- and extraliposomal adjustment in the
concentration of the free base of the drug. When the
intraliposomal pH-value is lower, the free DXR base is
protonated intraliposomally and new extraliposomal, non-
protonated DXR can diffuse into the liposome according to
the concentration gradient. Therefore a “proton pool” inside the
liposomes is necessary as a driving force for DXR loading.Fig. 4. Cryo-TEM micrograph of EPC/Chol (7/3 mol/mol) liposomes loaded
with DXR via a (NH4)2HPO4 gradient (intravesicular salt solution: 300 mM
(NH4)2HPO4, pH 7.4; extraliposomal buffer: 10 mMHEPES/140 mMNaCl, pH
7.4). Scale bar represents 200 nm.In the study presented a stable pH-gradient over the
loading period is maintained in situ by generation of a NH4
+-
gradient, i.e. by a high intraliposomal NH4
+ concentration and
an NH4
+ ion-free, extraliposomal buffer. Due to the NH4+-
gradient the pH-value decreases within the liposome from pH
7.4 to a pH lower than 5.5 (Table 2), even though the
extraliposomal buffer was also set to a pH of 7.4. The in situ
generation of the pH-gradient obviously results from the
higher permeation coefficient of ammonia with 1.3×10− 1 cm
s−1 [49] as compared to the permeation coefficient of protons
of 10−3 to 10−8 cm s−1 [50], which results in acidification of
the liposome interior. In the absence of an NH4
+-gradient there
is no decrease in intraliposomal pH-value. Instead, the
internal pH adjusts to that of the outer pH. Although up to
51% of DXR can be encapsulated in liposomes via a pH-
gradient by a NH4Cl-gradient (Fig. 5), higher results can be
obtained by synergistic effects (Fig. 2) which include
protonation and precipitation of DXR inside the liposome.
For the interaction of DXR with SO4
2− anions it was shown in
earlier studies that positively charged DXR precipitates with
negatively charged sulfate to form a gel-like structure within the
liposomes [30,32,51]. The cation–anion interaction in our
solubility studies showed consistently poor solubility of DXR in
a 300 mM sulfate solution in the investigated pH-range of
values close to the pKa of the amino group (pKa=8.1 [30])
where solubility drops to almost zero.
Fig. 6. Release of doxorubicin from (A) from EPC/Chol 7/3 (mol/mol)
liposomes loaded via an ammonium phosphate gradient and (B) commercial
product Caelyx®/Doxil® (y-axis extended). The drug release was analyzed in
10 mM HEPES, 140 mM NaCl buffer pH 7.4 (♦), pH 6.5 (▴) or pH 5.5 (●) at
37 °C. (n=3 in panel A, n=3 in panel B).
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tions have been carried out elsewhere [23]. However, no stable
complex or salt could be found.
Our study shows that the solubility of DXR increases in
300 mM citrate, 300 mM phosphate and 600 mM acetate
solution by decreasing the pH-value, although the concentration
of positively charged DXR increases. At pH values >7 the
solubility of DXR decreases. After deprotonation of DXR the
uncharged compound is nearly insoluble in the salt solution. It
seems probable that the cosmotropic (structure maker) proper-
ties of the counterion contribute to the solubility of DXR. The
salts used for loading, i.e., citrate, sulfate, phosphate and
acetate, are all components of the so-called Hofmeister or
lyotropic series [52,53]. This series reflects the ranking of ions
according to their binding strength of bulk water, and to the
concomitant decrease in the hydration of other compounds. The
precipitation caused by these compounds is then termed a salt-
out effect.
This also explains the requirement of the high salt
concentration of 300 mM for liposome loading (Table 2),
since this concentration is necessary to withdraw the hydration
shell of DXR. This salt-out effect plays a role not only for
proteins but for amphiphilic substances as well, which has been
shown in other studies [54]. The withdrawal of the hydration
shell also explains the self-aggregation of DXR driven by
hydrophobic interactions, which is highly dependent on the
respective buffer composition [55,56].
By using Na2HPO4-gradients with various pH-values it
could be demonstrated that with the synergism of protonation
and precipitation of DXR higher encapsulation efficiencies can
be achieved. The use of NH4
+ salt-gradients is more effectivethan a sodium salt gradient (Fig. 2), even if the intraliposomal
saline buffer solution is set to a lower pH-value (Fig. 3). In
contrast to sodium, ammonium acts as a reservoir, which
provides new free protons when DXR is protonated.
Aside from the hydrophilic interior of the liposome, the
lipophilic compartment of the bilayer also represents a factor
influencing loading. DXR consists of a hydrophobic co-
planar anthraquinone structure with the amino sugar in the
protonated state of a hydrophilic region. If DXR is not
retained in the hydrophilic compartment by protonation or
precipitation, there is the further possibility of the amphi-
philic molecule being incorporated in the bilayer. The
interaction of DXR with natural and model membranes
could already be demonstrated by fluorescent methods
[57,58].
Besides efficient loading, the release of the drug is also a
critical factor for a drug delivery system. As shown in our
studies, the release of DXR from liposomes which were
loaded by phosphate-gradient is highly dependent on the
extraliposomal pH-value. In this study pH-values 7.4, 6.5 or
5.5, similar to the situations in most tissues, tumors and
endosomes, were chosen to imitate the various pH environ-
ments of the liposome from the point of application to the
reaching of the target. In the case of phosphate-loaded DXR
liposomes a low extraliposomal pH-value results in facili-
tated DXR release, whereas liposomes loaded with sulfate-
gradient are not significantly influenced by the extra-
vesicular pH-value. The fact that sulfate is a salt of a
stronger acid as compared to phosphate, might explain the
difference in the release behavior of both DXR salts sulfate
and phosphate. The sulfate salt will not be protonated by
minor pH-shifts, i.e., from 7.4 to 5.5. In contrast, the charge
density of phosphate will be decreased by protonation of the
salt. This results in a lower interaction between the ion and
doxorubicin and a lower ability to retain DXR inside the
vesicles. This interpretation is supported by the findings of
Lee et al. [35].
In addition, the lyotropic series favors a higher solubility of
DXR phosphate inside the liposomes and consequently a higher
release rate upon acidification.
In summary, the presented remote loading process of DXR in
liposomes via (NH4)2HPO4-gradient depends on various
factors: intraliposomal salt concentration, water binding
potential of the salt, the pH-value in the liposome and the
presence of a “proton pool”, e.g. in the form of NH4
+ salts.
The loading of DXR in EPC/Chol liposomes via
(NH4)2HPO4-gradients represents a potent alternative proce-
dure to the methods used to date. It allows fast and effective
loading of the EPC/Chol liposomes at 7 °C as well as at
RT, and results in a liposomal drug delivery system which is
comparable to other liposomal DXR formulations in a
physiological pH environment, whereas under the pathophy-
siologic pH-conditions of tumor tissue or after endosomal
uptake an increased release of DXR from the vesicles is
achieved. The pH-triggered release of DXR offers new
perspectives for the improvement of the effectiveness of
tumor treatment.
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